The FDA has granted permission for Zyn nicotine pouches to be marketed with the claim that using them instead of cigarettes reduces the risk of several serious health conditions. Specifically, 20 Zyn products can now state that they put users at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. This decision follows a comprehensive scientific review by the FDA, including a public meeting in January where FDA scientists stated that "the totality of the evidence" supported the marketing claim.
This move is a significant win for Philip Morris International, the parent company of Zyn manufacturer Swedish Match. Philip Morris has consistently argued for the importance of providing adult smokers with accurate information about the relative risks of different nicotine products. Bret Koplow, acting director of the FDA's Center for Tobacco Products, emphasized that the FDA's review process ensures adult users receive clear, science-based information to make informed choices. The decision implies that the FDA views these products as having genuine harm-reduction potential, despite concerns raised by critics about their appeal to young people.
While this authorization allows Zyn to highlight its relative health benefits, it's crucial to note that the FDA has not declared these products "safe" or "FDA approved." The agency maintains that no tobacco product is safe, and individuals who do not use tobacco should not start. This authorization is specific to 20 Zyn products across various flavors and nicotine strengths (3mg and 6mg), including ZYN Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen. These specific products are the first nicotine pouches to receive marketing authorization with reduced-risk claims from the FDA. The products received marketing granted orders on January 16, 2025.
The FDA's decision was based on evidence that these products contain substantially lower amounts of harmful constituents compared to cigarettes and most smokeless tobacco products. The agency also considered a study indicating that a significant number of adult smokers and smokeless tobacco users completely switched to Zyn pouches. The FDA evaluated youth risk data, finding that current youth use of nicotine pouches remains low at 1.8% among U.S. middle and high school students, according to the 2024 National Youth Tobacco Survey. The authorization includes stringent marketing restrictions to prevent youth exposure, such as targeting ads only to adults 21 and older and avoiding content appealing to youth.
